Kirurgian vastuualue

Julkaisut 2016 (alustava)
Publications 2016 (preliminary)

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Agra R et al. Research update for articles published in EJCI in 2014.
2 Auvinen A et al. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
3 Auvinen A et al. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
4 Bokhorst LP et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
5 Gusev A et al. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.
6 Hakala T. Kilpirauhassyöpäpotilaiden uusien syöpien riski.
7 Kholová I. Changes in Classification of Follicular Thyroid Cancers.
8 Hakala T et al. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
9 Joentausta R et al. Tumor features and survival after radical prostatectomy among antidiabetic drug users.
10 Jokihaara J et al. Phosphate Binding with Sevelamer Preserves Mechanical Competence of Bone Despite Acidosis in Advanced Experimental Renal Insufficiency.
11 Kaapu K et al. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
12 Kaapu KJ et al. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
13 Kaapu KJ et al. Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.
14 Kar SP et al. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.
15 Keskiväli T et al. Statin use and risk of disease recurrence and death after radical prostatectomy.
16 Kilpeläinen T et al. Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer.
17 Kinnunen PT et al. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
18 Laine M et al. Rupture of Abdominal Aortic Aneurysms in Patients Under Screening Age and Elective Repair Threshold.
19 Laitinen VH et al. Germline copy number variation analysis in Finnish families with hereditary prostate cancer.
20 Leinonen KA et al. Amplification of the 9p13.3 chromosomal region in prostate cancer.
21 Luedeke M et al. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
22 Marttila T et al. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-a2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
23 Marttila T et al. Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
24 Massard C et al. Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.
25 Murtola T et al. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.
26 Murtola TJ et al. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
27 Wong SC et al. Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
28 Pakarainen T et al. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
29 Pennanen P et al. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.
30 Pesonen J et al. Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis.
31 Pietilä I et al. Who Has the Guts to Make This Choice?: Ideals of Masculinity in Men’s Justifications for Their Treatment Decisions for Localised Prostate Cancer.
32 Pyysalo MJ et al. Bacterial DNA findings in ruptured and unruptured intracranial aneurysms.
33 Pöyhönen A et al. Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men.
34 Raitoharju E et al. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study.
35 Rantanen T et al. Adenocarcinoma of the Oesophagus and Oesophagogastric Junction: Analysis of Incidence and Risk Factors.
36 Riikonen J et al. Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care.
37 Sairanen J et al. Interstitiaalisen virtsarakkotulehduksen eli virtsarakon kipuoireyhtymän hoito.
38 Salminen JK et al. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study.
39 Santos dos F et al. Automatic detection of carotid arteries in computed tomography angiography: a proof of concept protocol .
40 Sarre S et al. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
41 Schulman C et al. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
42 Seppälä I et al. Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke.
43 Seppänen L et al. A Developmental Perspective to Studying Objects in Robotic Surgery.
44 Seppänen L, Riikonen J. Learning interpretativeness for sustainability: exploring the selfconfrontation method in robotic surgert.
45 Sjöblom L et al. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
46 Suomalainen P et al. Traumakäsikirja, Vaikeasti vammautuneen potilaan hoito Taysissa 2016.
47 Syvälä H et al. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.
48 Teerlink C et al. Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21.
49 Teerlink CC et al. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.
50 Thomsen FB et al. Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study.
51 Vakhitov D et al. Successful endovascular treatment of mycotic aneurysms of the inferior mesenteric artery and the abdominal aorta.
52 Veitonmäki T. Non-steroidal anti-inflammatory drugs and cancer in Finnish men. An epidemiologic study on prostate cancer risk, survival and overall cancer mortality.
53 Veitonmäki T et al. Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial.
54 Venermo M et al. Randomized clinical trial comparing surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy for the treatment of great saphenous varicose veins.
55 von Essen M et al. Talin and vinculin are downregulated in atherosclerotic plaque; Tampere Vascular Study.
56 Vänni V et al. Vascular comorbidities and demographics of patients with ruptured abdominal aortic aneurysms.
57 Väärämäki S. Long-term Results of Endovascular Aortic Repair.
58 Väärämäki S et al. Long-Term Experience of Endovascular Repair for Thoracic Aortic Aneurysms and Dissections.
59 Väärämäki S et al. Hybrid Repair of Thoracoabdominal Aortic Aneurysms Is a Durable Option for High-Risk Patients in the Endovascular Era.

Julkaisutietokanta 19.10.2017 Publications Data Base 19.10.2017